Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
[1] Schedule 1, omit entry for Estradiol with dydrogesterone
[2] Schedule 1, after entry for Ibrutinib in the form Capsule 140 mg [Maximum quantity or number of units: 120; Maximum number of repeats: 5]
insert:
| Tablet 280 mg | 20 | 30 | 5 | |
| Tablet 420 mg | 20 | 30 | 5 | |
| Tablet 560 mg | 20 | 30 | 5 | |
[3] Schedule 2
insert as first entry:
Acarbose | Tablet 50 mg | 50 | 180 | 5 | |
| Tablet 100 mg | 50 | 180 | 5 | |
[4] Schedule 2, after entry for Alendronic acid
insert:
Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | 50 | 8 | 5 | |
| Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | 50 | 8 | 5 | |
[5] Schedule 2, after entry for Allopurinol in the form Tablet 300 mg
insert:
Alogliptin | Tablet 6.25 mg (as benzoate) | 50 | 56 | 5 | |
| Tablet 12.5 mg (as benzoate) | 50 | 56 | 5 | |
| Tablet 25 mg (as benzoate) | 50 | 56 | 5 | |
Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride | 50 | 112 | 5 | |
[6] Schedule 2, after entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)
insert:
| Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 50 | 60 | 5 | |
[7] Schedule 2, after entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg
insert:
Anastrozole | Tablet 1 mg | 50 | 60 | 5 | |
[8] Schedule 2, after entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg
insert:
Bromocriptine | Tablet 2.5 mg (as mesilate) | 50 | 120 | 5 | |
Cabergoline | Tablet 500 micrograms | 50 | 16 | 5 | |
[9] Schedule 2, after entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg
insert:
Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL | 50 | 2 | 5 | |
| Tablet 200 mg (controlled release) | 50 | 400 | 2 | |
| Tablet 400 mg (controlled release) | 50 | 400 | 2 | |
Carbimazole | Tablet 5 mg | 50 | 400 | 2 | |
[10] Schedule 2, after entry for Chlortalidone
insert:
Ciclosporin | Capsule 10 mg | 50 | 240 | 3 | |
| Capsule 25 mg | 50 | 120 | 3 | |
| Capsule 50 mg | 50 | 120 | 3 | |
| Capsule 100 mg | 50 | 120 | 3 | |
| Oral liquid 100 mg per mL, 50 mL | 50 | 4 | 3 | |
[11] Schedule 2, after entry for Clopidogrel with aspirin
insert:
Cortisone | Tablet containing cortisone acetate 5 mg | 50 | 100 | 4 | |
| Tablet containing cortisone acetate 25 mg | 50 | 120 | 4 | |
Cyproterone | Tablet containing cyproterone acetate 50 mg | 50 | 40 | 5 | |
| | 50 | 200 | 5 | |
| Tablet containing cyproterone acetate 100 mg | 50 | 100 | 5 | |
[12] Schedule 2, after entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate)
insert:
Dapagliflozin | Tablet 10 mg (as propanediol monohydrate) | 50 | 56 | 5 | |
Dapagliflozin with metformin | Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride | 50 | 56 | 5 | |
| Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | 50 | 56 | 5 | |
Desmopressin | Tablet containing desmopressin acetate 200 micrograms | 50 | 60 | 5 | |
| | 50 | 180 | 5 | |
| Wafer 120 micrograms (as acetate) | 50 | 60 | 5 | |
| Wafer 240 micrograms (as acetate) | 50 | 60 | 5 | |
Dexamethasone | Tablet 500 micrograms | 50 | 60 | 4 | |
Dutasteride | Capsule 500 micrograms | 50 | 60 | 5 | |
Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | 50 | 60 | 5 | |
Empagliflozin | Tablet 10 mg | 50 | 60 | 5 | |
| Tablet 25 mg | 50 | 60 | 5 | |
Empagliflozin with linagliptin | Tablet containing 10 mg empagliflozin with 5 mg linagliptin | 50 | 60 | 5 | |
| Tablet containing 25 mg empagliflozin with 5 mg linagliptin | 50 | 60 | 5 | |
Empagliflozin with metformin | Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride | 50 | 120 | 5 | |
[13] Schedule 2, after entry for Eplerenone in the form Tablet 50 mg
insert:
Eprosartan | Tablet 600 mg (as mesilate) | 50 | 56 | 5 | |
Estradiol | Pessary (modified release) 10 micrograms (as hemihydrate) | 50 | 36 | 2 | |
| Tablet 2 mg | 50 | 112 | 2 | |
| Tablet containing estradiol valerate 1 mg | 50 | 112 | 2 | |
| Tablet containing estradiol valerate 2 mg | 50 | 112 | 2 | |
| Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | 50 | 2 | 5 | |
Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg | 50 | 2 | 5 | |
| Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg | 50 | 2 | 5 | |
Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate | 50 | 2 | 5 | |
| Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | 50 | 2 | 5 | |
Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | 50 | 2 | 5 | |
Estriol | Pessaries 500 micrograms, 15 | 50 | 2 | 2 | |
| Vaginal cream 1 mg per g, 15 g | 50 | 2 | 1 | |
Ethosuximide | Oral solution 250 mg per 5 mL, 200 mL | 50 | 2 | 5 | |
Everolimus | Tablet 0.75 mg | 50 | 240 | 3 | |
| Tablet 1 mg | 50 | 240 | 3 | |
Exemestane | Tablet 25 mg | 50 | 60 | 5 | |
[14] Schedule 2, after entry for Gemfibrozil
insert:
Glibenclamide | Tablet 5 mg | 50 | 200 | 5 | |
Gliclazide | Tablet 60 mg (modified release) | 50 | 120 | 5 | |
| Tablet 80 mg | 50 | 200 | 5 | |
Glimepiride | Tablet 1 mg | 50 | 60 | 5 | |
| Tablet 2 mg | 50 | 60 | 5 | |
| Tablet 3 mg | 50 | 60 | 5 | |
| Tablet 4 mg | 50 | 60 | 5 | |
Glipizide | Tablet 5 mg | 50 | 200 | 5 | |
[15] Schedule 2, after entry for Hydrochlorothiazide with amiloride
insert:
Hydrocortisone | Tablet 4 mg | 50 | 100 | 4 | |
[16] Schedule 2, after entry for Isosorbide mononitrate in the form Tablet 120 mg (sustained release)
insert:
Labetalol | Tablet containing labetalol hydrochloride 100 mg | 50 | 200 | 5 | |
Lacosamide | Oral solution 10 mg per mL, 200 mL | 50 | 4 | 5 | |
| | 50 | 12 | 5 | |
| Tablet 50 mg | 50 | 112 | 5 | |
| Tablet 100 mg | 50 | 112 | 5 | |
| Tablet 150 mg | 50 | 112 | 5 | |
| Tablet 200 mg | 50 | 112 | 5 | |
Lamotrigine | Tablet 5 mg | 50 | 112 | 5 | |
| Tablet 25 mg | 50 | 112 | 5 | |
| Tablet 50 mg | 50 | 112 | 5 | |
| Tablet 100 mg | 50 | 112 | 5 | |
| Tablet 200 mg | 50 | 112 | 5 | |
Lanthanum | Tablet, chewable, 500 mg (as carbonate hydrate) | 50 | 180 | 5 | |
| Tablet, chewable, 750 mg (as carbonate hydrate) | 50 | 180 | 5 | |
| Tablet, chewable, 1000 mg (as carbonate hydrate) | 50 | 180 | 5 | |
Leflunomide | Tablet 10 mg | 50 | 60 | 5 | |
| Tablet 20 mg | 50 | 60 | 5 | |
[17] Schedule 2, after entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg
insert:
Letrozole | Tablet 2.5 mg | 50 | 60 | 5 | |
Levetiracetam | Oral solution 100 mg per mL, 300 mL | 50 | 2 | 5 | |
| Tablet 250 mg | 50 | 120 | 5 | |
| Tablet 500 mg | 50 | 120 | 5 | |
| Tablet 1 g | 50 | 120 | 5 | |
Linagliptin | Tablet 5 mg | 50 | 60 | 5 | |
Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride | 50 | 120 | 5 | |
Liothyronine | Tablet containing liothyronine sodium 20 micrograms | 50 | 200 | 2 | |
[18] Schedule 2, after entry for Lisinopril in the form Tablet 20 mg
insert:
Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 5 mg | 50 | 112 | 2 | |
| Tablet containing medroxyprogesterone acetate 10 mg | 50 | 60 | 2 | |
| | 50 | 200 | 2 | |
| Tablet containing medroxyprogesterone acetate 100 mg | 50 | 200 | 2 | |
| Tablet containing medroxyprogesterone acetate 200 mg | 50 | 120 | 2 | |
| Tablet containing medroxyprogesterone acetate 250 mg | 50 | 120 | 2 | |
| Tablet containing medroxyprogesterone acetate 500 mg | 50 | 60 | 2 | |
[19] Schedule 2, after entry for Mesalazine in the form Tablet 1.6 g (enteric coated)
insert:
Metformin | Tablet containing metformin hydrochloride 500 mg | 50 | 200 | 5 | |
| Tablet containing metformin hydrochloride 850 mg | 50 | 120 | 5 | |
| Tablet containing metformin hydrochloride 1 g | 50 | 180 | 5 | |
| Tablet (extended release) containing metformin hydrochloride 500 mg | 50 | 240 | 5 | |
| Tablet (extended release) containing metformin hydrochloride 1 g | 50 | 120 | 5 | |
Methenamine | Tablet containing methenamine hippurate 1 g | 50 | 200 | 5 | |
Methotrexate | Injection 50 mg in 2 mL vial | 50 | 10 | 5 | |
[20] Schedule 2, entry for Metoprolol succinate in the form Tablet 190 mg (controlled release)
insert:
Minoxidil | Tablet 10 mg | 50 | 200 | 5 | |
[21] Schedule 2, after entry for Moxonidine in the form Tablet 400 micrograms
insert:
Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | 50 | 600 | 5 | |
| Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | 50 | 2 | 5 | |
| Tablet containing mycophenolate mofetil 500 mg | 50 | 300 | 5 | |
| Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | 50 | 240 | 5 | |
| Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | 50 | 240 | 5 | |
[22] Schedule 2, after entry for Nifedipine in the form Tablet 60 mg (controlled release)
insert:
Norethisterone | Tablet 5 mg | 50 | 60 | 2 | |
[23] Schedule 2, after entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)
insert:
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | 50 | 60 | 5 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | 50 | 60 | 5 | |
[24] Schedule 2, after entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg
insert:
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | 50 | 60 | 5 | |
[25] Schedule 2, after entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg
insert:
Oxcarbazepine | Oral suspension 60 mg per mL, 250 mL | 50 | 4 | 5 | |
| Tablet 300 mg | 50 | 200 | 5 | |
| Tablet 600 mg | 50 | 200 | 5 | |
Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | 50 | 200 | 5 | |
| Transdermal patches 36 mg, 8 | 50 | 2 | 5 | |
[26] Schedule 2, after entry for Penicillamine in the form Tablet 250 mg
insert:
Perampanel | Tablet 4 mg (as hemisesquihydrate) | 50 | 56 | 2 | |
| | 50 | 56 | 5 | |
| Tablet 6 mg (as hemisesquihydrate) | 50 | 56 | 2 | |
| | 50 | 56 | 5 | |
| Tablet 8 mg (as hemisesquihydrate) | 50 | 56 | 5 | |
| Tablet 10 mg (as hemisesquihydrate) | 50 | 56 | 5 | |
| Tablet 12 mg (as hemisesquihydrate) | 50 | 56 | 5 | |
[27] Schedule 2, after entry for Perindopril with indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg
insert:
Phenoxymethylpenicillin | Capsule 250 mg phenoxymethylpenicillin (as potassium) | 50 | 100 | 5 | |
| Tablet 250 mg phenoxymethylpenicillin (as potassium) | 50 | 100 | 5 | |
Phenytoin | Capsule containing phenytoin sodium 30 mg | 50 | 400 | 2 | |
| Capsule containing phenytoin sodium 100 mg | 50 | 400 | 2 | |
| Oral suspension 30 mg per 5 mL, 500 mL | 50 | 2 | 3 | |
| Tablet 50 mg | 50 | 400 | 2 | |
Pioglitazone | Tablet 15 mg (as hydrochloride) | 50 | 56 | 5 | |
| Tablet 30 mg (as hydrochloride) | 50 | 56 | 5 | |
| Tablet 45 mg (as hydrochloride) | 50 | 56 | 5 | |
Pizotifen | Tablet 500 micrograms (as malate) | 50 | 200 | 2 | |
[28] Schedule 2, after entry for Prazosin in the form Tablet 5 mg (as hydrochloride)
insert:
Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | 50 | 2 | 5 | |
| Tablet 1 mg | 50 | 200 | 4 | |
| Tablet 5 mg | 50 | 120 | 4 | |
Prednisone | Tablet 1 mg | 50 | 200 | 4 | |
| Tablet 5 mg | 50 | 120 | 4 | |
Probenecid | Tablet 500 mg | 50 | 200 | 5 | |
Propantheline | Tablet containing propantheline bromide 15 mg | 50 | 400 | 5 | |
[29] Schedule 2, after entry for Propranolol in the form Tablet containing propranolol hydrochloride 40 mg
insert:
Propylthiouracil | Tablet 50 mg | 50 | 400 | 2 | |
Quinagolide | Tablet 75 micrograms (as hydrochloride) | 50 | 60 | 5 | |
[30] Schedule 2, after entry for Sacubitril with valsartan in the form Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg
insert:
Saxagliptin | Tablet 2.5 mg (as hydrochloride) | 50 | 56 | 5 | |
| Tablet 5 mg (as hydrochloride) | 50 | 56 | 5 | |
Saxagliptin with dapagliflozin | Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg | 50 | 56 | 5 | |
Saxagliptin with metformin | Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride | 50 | 56 | 5 | |
| Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | 50 | 56 | 5 | |
Sevelamer | Tablet containing sevelamer carbonate 800 mg | 50 | 360 | 5 | |
| Tablet containing sevelamer hydrochloride 800 mg | 50 | 360 | 5 | |
[31] Schedule 2, after entry for Simvastatin in the form Tablet 80 mg
insert:
Sirolimus | Oral solution 1 mg per mL, 60 mL | 50 | 2 | 3 | |
| Tablet 0.5 mg | 50 | 200 | 3 | |
| Tablet 1 mg | 50 | 200 | 3 | |
| Tablet 2 mg | 50 | 200 | 3 | |
Sitagliptin | Tablet 25 mg | 50 | 56 | 5 | |
| Tablet 50 mg | 50 | 56 | 5 | |
| Tablet 100 mg | 50 | 56 | 5 | |
Sitagliptin with metformin | Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 112 | 5 | |
| Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | 50 | 56 | 5 | |
Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | 50 | 200 | 5 | |
Sodium bicarbonate | Capsule 840 mg | 50 | 200 | 2 | |
[32] Schedule 2, after entry for Spironolactone in the form Tablet 25 mg
insert:
[33] Schedule 2, after entry for Spironolactone in the form Tablet 100 mg
insert:
Sucroferric oxyhydroxide | Tablet, chewable, 2.5 g (equivalent to 500 mg iron) | 50 | 180 | 5 | |
[34] Schedule 2, after entry for Sulfasalazine in the form Tablet 500 mg (enteric coated)
insert:
Sulthiame | Tablet 50 mg | 50 | 400 | 2 | |
| Tablet 200 mg | 50 | 400 | 2 | |
Tacrolimus | Capsule 0.5 mg | 50 | 200 | 3 | |
| Capsule 0.5 mg (once daily prolonged release) | 50 | 60 | 3 | |
| Capsule 0.75 mg | 50 | 200 | 3 | |
| Capsule 1 mg | 50 | 200 | 3 | |
| Capsule 1 mg (once daily prolonged release) | 50 | 120 | 3 | |
| Capsule 2 mg | 50 | 200 | 3 | |
| Capsule 3 mg (once daily prolonged release) | 50 | 100 | 2 | |
| Capsule 5 mg | 50 | 100 | 3 | |
| Capsule 5 mg (once daily prolonged release) | 50 | 60 | 3 | |
Tamoxifen | Tablet 20 mg (as citrate) | 50 | 60 | 5 | |
| | 50 | 120 | 5 | |
[35] Schedule 2, after entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg
insert:
Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled cartridge | 50 | 2 | 5 | |
Testosterone | Transdermal gel 50 mg in 5 g sachet, 30 | 50 | 2 | 5 | |
| Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 | 50 | 2 | 4 | |
| Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses | 50 | 2 | 5 | |
[36] Schedule 2, after entry for Thiamine
insert:
Tiagabine | Tablet 5 mg (as hydrochloride) | 50 | 200 | 5 | |
| Tablet 10 mg (as hydrochloride) | 50 | 200 | 5 | |
| Tablet 15 mg (as hydrochloride) | 50 | 200 | 5 | |
[37] Schedule 2, after entry for Ticagrelor
insert:
Tobramycin | Capsule containing powder for oral inhalation 28 mg (for use in podhaler) | 50 | 448 | 2 | |
| Solution for inhalation 300 mg in 5 mL | 50 | 112 | 2 | |
Topiramate | Capsule 15 mg | 50 | 120 | 5 | |
| Capsule 25 mg | 50 | 120 | 5 | |
| Capsule 50 mg | 50 | 120 | 5 | |
| Tablet 25 mg | 50 | 120 | 5 | |
| Tablet 50 mg | 50 | 120 | 5 | |
| Tablet 100 mg | 50 | 120 | 5 | |
| Tablet 200 mg | 50 | 120 | 5 | |
Toremifene | Tablet 60 mg (as citrate) | 50 | 60 | 5 | |
[38] Schedule 2, after entry for Trandolapril with verapamil in the form Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release)
insert:
Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | 50 | 4 | 2 | |
| Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | 50 | 4 | 2 | |
| Tablet, crushable, containing sodium valproate 100 mg | 50 | 400 | 2 | |
| Tablet (enteric coated) containing sodium valproate 200 mg | 50 | 400 | 2 | |
| Tablet (enteric coated) containing sodium valproate 500 mg | 50 | 400 | 2 | |
[39] Schedule 2, after entry for Verapamil in the form Tablet containing verapamil hydrochloride 240 mg (sustained release)
insert:
Vigabatrin | Oral powder, sachet 500 mg | 50 | 120 | 5 | |
| Tablet 500 mg | 50 | 200 | 5 | |
Vildagliptin | Tablet 50 mg | 50 | 120 | 5 | |
Vildagliptin with metformin | Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride | 50 | 120 | 5 | |
| Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride | 50 | 120 | 5 | |
Zonisamide | Capsule 25 mg | 50 | 112 | 5 | |
| Capsule 50 mg | 50 | 112 | 5 | |
| Capsule 100 mg | 50 | 224 | 5 | |
